Helius Medical Technologies Announces Extension of Agreement with US Army

Helius Medical Technologies (TSX:HSM; OTCQB:HSDT) announced its subsidiary NeuroHabilitation executed an extension to its research and development agreement with the US Army Medical Research and Materiel Command through 2018.

As quoted in the press release:

[NeuroHabilitation] extended the deadline for commercialization of the PoNS Therapy to December 31, 2021.

The CRADA partners Helius and the USAMRMC in the clinical development and commercialization of the Company’s Portable Neuromodulation Stimulator (PoNS) device, a non-invasive brain stimulation device, currently being developed for the treatment of chronic balance disorder in patients with mild to moderate traumatic brain injury.

The CRADA is also intended to support the development of other potential indications of the device, relevant to injured service members who have suffered a traumatic brain injury, such as treating tinnitus, post-traumatic stress, sleep disturbances or chronic pain.

Click here to read the full press release.

Get the Latest Medical Device Investing Stock Information

Get the latest information about companies associated with Medical Device Investing delivered directly to your inbox.

Medical Device

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.

Comments

Leave a Reply